Objective: Recent observations suggest the existence of a myocardial endothelin (ET) system and its possible involvement in left-ventricular myocardial hypertrophy and failure. However, nothing is known about the role of myocardial ET in right-ventricular hypertrophy. Methods: Rats (80-100 g) were given an intraperitoneal injection of saline (controls) or monocrotaline (50 mg / kg) resulting in pulmonary hypertension-induced myocardial hypertrophy (n511 in both groups). After 10 weeks, the animals were sacrificed and hearts perfused in vitro to determine levels of big ET-1 and ET-1 in coronary effluent, interstitial fluid and ventricular tissue homogenates; plasma levels were also determined. Results: In monocrotaline-treated animals, weights of right ventricles were 1.5-and of right atria 1.8-fold higher than in controls ( p,0.05), indicating substantial right-ventricular hypertrophy as also evident from greatly increased myocardial production of atrial natriuretic peptide. Left-ventricular weights were not different. Release of big ET-1 in coronary effluent, and of ET-1 in coronary effluent and interstitial transudate were similar in control and hypertrophic hearts ( p.0.05). Disruption of endothelium with collagenase reduced release of both peptides close to zero, indicating endothelial (not myocardial) origin of the peptides. Levels of big ET-1 and ET-1 were similar in left ventricles of both experimental groups, but lower in right ventricles of hypertrophic than control hearts ( p,0.05), reflecting increased tissue mass rather than reduced peptide production. On the other hand, plasma levels of both peptides and of ANP were twofold and levels of angiotensin II 1.3-fold higher in rats with right-heart hypertrophy than in controls ( p,0.05 in each case). Conclusion: These data do not support a role for local cardiac ET-1 and / or big ET-1 in right-ventricular hypertrophy, but point to blood-borne endothelins as possible mediators.
Introduction
implicated a potential role for angiotensin II in pressure overload cardiac hypertrophy by using angiotensin conAlthough cardiac hypertrophy is an adaptive reaction of verting enzyme (ACE) inhibitors [1] and angiotensin II cardiac myocytes to an increased work load, ventricular receptor antagonists [2] . More recently, interest has fohypertrophy is associated with a higher incidence of heart cused on the role of endothelins, particularly endothelin-1 failure. Experimental and clinical studies have demon-(ET-1) which stimulates growth of cultured carstrated the activation of the renin-angiotensin and endodiomyocytes [3, 4] and cardiac fibroblasts [5] . It was shown thelin systems in myocardial hypertrophy and congestive that angiotensin II induces the expression and secretion of heart failure, but the mechanisms involved in these ET-1 in cultured cardiomyocytes [6] and that in myocytes pathologies are not fully understood. Previous studies have subjected to mechanical stress, secretion of both ET-1 and angiotensin II is enhanced and results in a synergistic hypertrophic response [7] . From these data the authors ET-1 in all of the above studies are much higher than ET-1 2.2. Animals plasma levels (,1 to |10 pg / ml [,0.4 to |4 pmol / l]), and the interstitial levels in hypertrophy are not known.
Sprague-Dawley rats weighting 80-100 g were divided Several recent observations suggest that ET-1 is ininto two groups: One group of animals was given a single volved in the aetiology of congestive heart failure as well.
intraperitoneal injection of monocrotaline (50 mg / kg; First, ET-1 is a potent vasoconstrictor and positive inothypertrophy group), the second group was injected with rope [8] that may affect the loading conditions of the the same volume of saline (control group). The treatment infarcted heart and contribute to ventricular remodelling; group soon showed a lack of appetite, indicating general second, levels of plasma ET-1 are increased 2-3-fold in illness as was observed previously [20] . Hence, the control various animal models of heart failure [9, 10] and in cardiac group was given each day only the amount of nutrition that patients [11] [12] [13] ; third, up-regulation of the myocardial ET had been consumed the previous day by the treated rats system may contribute to the progression of heart failure which had a free supply of food. Altogether 24 rats were because in vivo antagonism of ET receptors improves treated with monocrotaline. Three weeks after injection the survival of animals with chronic heart failure [10] , defirst rats started to die due to the toxic effects of the creases left-ventricular hypertrophy and cardiac fibrosis alkaloid; 4 weeks after injection 13 rats (54%) had died, [14] , partially prevents left-ventricular dilatation, and but afterwards no more cases of death were observed. improves haemodynamics [15, 16] . Finally, antagonism of Those rats that survived this period of mortality were ET receptors in patients with low-output heart failure sacrificed 10 weeks after monocrotaline injection and their improved the haemodynamic profile [17] .
hearts used for the Langendorff experiments in this study. In spite of this evidence the respective roles of the Although no pleural or peritoneal effusions were observed, cardiac and circulating ET systems in the development of monocrotaline-treated animals had substantial right-venmyocardial hypertrophy and heart failure are far from tricular hypertrophy as described in Results. The invesestablished. Thus, little is known about the role of ET-1 in tigation conforms with the Guide for the Care and Use of right heart hypertrophy and failure and the interaction of Laboratory Animals published by the US National Instithe cardiac ET system with other potential mediators like tutes of Health (NIH publication No. 85-23, revised 1985) . the local renin-angiotensin system and atrial natriuretic peptide (ANP). Therefore, several aims were pursued in 2.3. Heart perfusions this study: i) to determine the release into coronary effluent of ET-1, its precursor big ET-1, angiotensin II, and ANP, Rats were anaesthetized with diethyl ether, the hearts an established marker of load-associated ventricular rearrested in ice-cold Krebs-Henseleit perfusion medium and modelling; ii) to measure ET-1 and big ET-1 levels in mounted within 2 min of thoracotomy. Retrograde perfuinterstitial fluid and ventricular homogenates to account for sion (Langendorff mode) was established at a rate of 10.0 possible changes in the direction of mediator release in ml / min per g heart wet weight with a modified Krebshypertrophic hearts, and iii) to determine the cellular origin Henseleit bicarbonate buffer (composition in mmol / l: of ET-1 and big ET-1 in isolated perfused rat hearts with NaCl 118, NaHCO 25, KH PO oratories, purchased through Baxter GmbH, Unterschleis-sheim, Germany). LVEDP was set at 0 mm Hg at start of experiment and remained at this level up to collagenase perfusion.
Experimental protocol
After equilibration (15 min) hearts were perfused for 120 min under normoxic conditions with Krebs-Henseleit buffer at constant flow and haemodynamic parameters were recorded and effluent and transudate samples collected as described below. Thereafter, endothelial cells were disrupted through perfusion with collagenase (0.1% dissolved in perfusion buffer) for 2 min, followed by washout of collagenase for 8 min with normal perfusion buffer. Because the aortic valve is closed in retrograde perfusion, no collagenase entered the ventricular lumen, leaving endocardial endothelium intact. To validate coronary endothelium disruption, the effects of the endothelium-dependent agonist acetylcholine (10 nmol / l) and the endothelium-independent agonist spermine / NO (100 mmol / l) were tested (at 130-150 min after equilibration). As expected, collagenase treatment completely abolished the relaxant effect of acetylcholine, while relaxation by spermine / NO was only little affected, as reported previously [22] . Hearts were then perfused for another 120 min, haemodynamic parameters recorded, and effluent and transudate samples collected as described below (end of experiment at 270 min after equilibration; compare Fig. 1 ). After the experiment the left and right atria were removed from the hearts and the free wall of the right ventricle and Hearts were equilibrated (15 min, not shown) and perfused in vitro with the left ventricle plus interventricular septum were sepacrystalloid perfusion medium for 120 min, followed by disruption of the rated. All specimens were weighted and frozen at 2208C. Coronary effluent which left the heart through the no significant differences between experimental groups. pulmonary artery was collected quantitatively in intervals of 7.5 min in exchangeable vials. Interstitial fluid (transudate) produced by ventricles and appearing on their 2.6. Determination of endothelins, angiotensin II and surface was collected under a latex cap using slight suction ANP and sampled quantitatively in intervals of 30 min. In this model all irrigated parts, i.e. myocardium and vascular 2.6.1. ET-1 tissues of both right and left heart, contribute to generation ET-1 was concentrated by solid-phase extraction from of transudate according to their surface area. Transudate individual effluent samples (|75 ml), the combined transflow rate was 50-78 ml / min prior to endothelium disrupudates from 2 hearts (3-4.5 ml), or 1 ml of plasma (diluted tion and about 4 times higher after disruption. All details with 9 ml of RIA buffer), followed by quantitative of the procedure were reported previously [21, 23] . Samradioimmunoassay (RIA) as described previously [21] . ples were collected on ice and quickly frozen at 2208C Briefly, the samples were loaded onto pre-conditioned C2 pending analysis. After removal of the heart, blood was Spe-edE cartridges (Inovec, Vienna, Austria), ET-1 was collected from the thoracic cavity into plastic tubes spiked eluted with acetonitrile (70%), the eluate freeze-dried and with EDTA, aprotinine and heparin, giving approximate the ET-1 contained in the sediment was dissolved in buffer final concentrations of 2 mmol / l, 40 mg / ml, and 100 U / ml and determined by RIA using an antibody specific for heparin, respectively. Plasma was allowed to separate from ET-1 (RAS 6901; Peninsula, Belmont, CA, USA). Stancells (1 h, 48C), centrifuged and stored at 2708C pending dards and samples were incubated with antibody for 48 h, analysis. followed by a second incubation over 20 h with [ I]ET-1 at 48C. Bound radioactivity was separated using poly-(n53). No angiotensin II was detected in coronary efethylene glycol and counted in a g-counter. The IC value fluents or transudates pooled from 4 hearts.
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of the standard curve was 1.160.04 pg / tube, and the detection limit was 0.08 pg / tube. The intra-and inter-2.6.4. ANP assay coefficients of variation for the determination of 1 pg
The extraction and assay of ANP in plasma and cor-ET-1 dissolved in 100 ml assay buffer were 4.5% and onary effluents was reported in detail previously [25] . 5.4%, respectively (n55). Incubation of ET-1 at 10 pg / ml Briefly, plasma (0.25 ml) was acidified with 0.25 ml and of big ET-1 at 1 ng / ml (i.e., respective IC values) 50 trifluoroacetic acid (TFA; 0.5%), loaded on C18 columns, with collagenase (0.05%, 378C, 2 h) did not in the least ANP was eluted with 2 ml of 80% acetonitrile in 0.1% affect breakdown of either peptide (n55).
TFA, the eluate freeze-dried and the ANP contained in the sediment was dissolved in buffer and determined by RIA.
Big ET-1
The recovery of the extraction procedure was tested with 125 For the determination of big ET-1, a similar procedure [ I]ANP and was 7461% (n56). Effluent samples were was used: pooled effluents from 2 hearts (|150 ml) or 1 ml appropriately diluted with RIA buffer (usually 3-fold) and of plasma diluted with 9 ml RIA buffer were loaded onto used in the assay without prior extraction. Samples and C2 cartridges and big ET-1 was eluted and processed as standards (0.0625-256 fmol / tube) were incubated with described above for ET-1. The concentration of big ET-1 anti-atrial natriuretic factor (rat) serum (Phoenix Pharmain transudate was below the detection limit even when ceuticals, Belmont, CA, USA; diluted 1:2 with RIA buffer) transudates of 4 hearts were pooled. Big ET-1 was for 24 h, followed by addition of |10 000 cpm of 125 determined by RIA using a polyclonal antiserum that we [ I]ANP and incubation for another 20 h at 48C. Precipihad raised against big ET-1 (1-39; rat) in rabbits. Standard tation of bound ANP was achieved through addition of 100 solutions of big ET-1 (1-39; rat) (2-512 pg / assay) were ml g-globulin (10 mg / ml) and 750 ml polyethylene glycol prepared in RIA buffer and incubated with antiserum 6000 (20%). The IC value of the standard curve was 50 (dilution: 1:10 000) for 48 h at 48C, followed by addition 1.660.08 fmol / tube and the detection limit was The intra-and inter-assay volume: 300 ml). Bound radioactivity was separated as coefficients of variation with 2 fmol ANP in 100 ml buffer described for ET-1 and counted. The detection limit was were 4.6 and 6.9%, respectively (n53). |2 pg per assay tube (|10% displacement of the radioactive tracer) and the IC value of the standard curve was 45 50 2.7. Tissue extraction of ET-1 and big ET-1 pg / tube. Non-specific binding was determined with 10 ng of big ET-1 (1-39; rat) and was typically 4% of total ET-1 and big ET-1 were extracted from ventricular binding. Cross-reaction of the antiserum was 9% with big tissue following published methods [10] . Right ventricles ET-1 (1-38; human), 47% with big ET-1 (1-39; porcine), (pooled from two hearts) or left ventricles were homogen-16% with big ET-1 (22-39; bovine), and zero with ET-1, ized at 48C with a Polytron homogenizer (Ultra Turrax) in ANP (1-28; rat) and angiotensin II. The intra-and inter-2 ml of ice-cooled acetic acid (0.2 mol / l) containing 0.5 assay coefficients of variation for the determination of 100 mol / l NaCl. The suspension was centrifuged at 20003g pg big ET-1 in 100 ml assay buffer were 2.9 and 4.7%, for 15 min at 48C and the supernatant solution was applied respectively (n54).
to solid phase extraction and quantitative RIA as described zation was 8862% and 9262%, respectively (n54). applied to C2 cartridges, angiotensin II was eluted from the cartridges with acetonitrile (70%), eluted angiotensin II was dried and reconstituted in 250 ml buffer for RIA using 2.8. Presentation of data and statistical analysis commercial materials as described previously [24] . Standards (0.0625-256 fmol / tube) and samples were incubated Group data are presented as arithmetic mean |24 h at 48C with anti-angiotensin II antiserum (Amervalues6SEM. A one-way analysis of variance (ANOVA) sham; Vienna, Austria), followed by addition of followed by the Scheffe test was performed for com-
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[ I]angiotensin II for |20 h. Precipitation of bound parisons of functional parameters measured over time. The angiotensin II was achieved through addition of 100 ml secretion data for ET-1 and big ET-1 are presented as g-globulin (10 mg / ml) and 750 ml polyethylene glycol secretion rates (pg / min per g wet heart weight) and 6000 (20%). The IC value for the standard curve was respective concentrations (pg / ml coronary effluent or 50 1561.1 fmol / tube; the detection limit was 0.0860.02 interstitial transudate) to account for a possible dependence fmol / tube (n54). The intra-and inter-assay coefficients of of peptide secretion on fluid flow. A probability of ,0.05 variation for the determination of 20 fmol angiotensin II in was considered as significant and is denoted by an asterisk. 100 ml assay buffer were 6.3 and 7.8%, respectively P values ,0.01 were not indicated separately.
Results

Weights of organs
Although body weights did not differ between the two groups (301627 g and 294620 g, respectively) right heart weight was significantly higher in monocrotaline-treated rats indicating substantial right-ventricular hypertrophy. Wet weight of right ventricles was 169610 mg in controls and 254613 mg in the hypertrophy group (1.5-fold increase; n511); the corresponding weights of right auricles were 3862 mg and 6764 mg, respectively (1.8-fold increase; n511; p,0.05 in both cases). 
Cardiac functional parameters
The functional parameters LVDevP, CPP, and LVEDP were remarkably stable and not different between hearts from controls and monocrotaline-treated rats (compare time-courses in Fig. 1 ). Spontaneous heart rate was 30365 21 21 min in control and 30468 min in treated animals (4 measurements at 30 min-intervals; P.0.05, n511 hearts). Disruption of endothelium with collagenase led to similar functional changes in the control and monocrotalinetreated groups, i.e. a decline of LVDevP (242%), a rise in The abluminal release of ET-1 was measured in interstitial 3.3. Mediator levels in plasma transudate as described previously [21, 22] and is depicted in Fig. 4 . Much less ET-1 (|4%) appeared in interstitial The concentrations of ET-1, big ET-1, ANP and antransudate than coronary effluent, and after disruption of giotensin II in plasma were significantly elevated in endothelium, release fell to below detection limit. Howmonocrotaline-treated rats (Fig. 2) . ET-1 rose from ever, due to the large differences in transudate and 10.760.5 to 16.660.6 pg / ml (1.5-fold), big ET-1 from coronary perfusate flow, the ET-1 concentration was |5-469.4640.3 to 1046.1642.0 pg / ml (2.2-fold), ANP from fold higher in interstitial transudate (Fig. 4B) than the 51.362.6 to 97.766.5 pmol / l (1.9-fold increase) and coronary effluent ( Fig. 3B ; n58 hearts in each case). levels of angiotensin II from 63.562.0 to 84.062.1 pmol / l
Release of big ET-1 into coronary effluent and the (1.3-fold) (n510, p,0.05 in each case).
resulting concentrations are shown is Figs. 5A and B.
Monocrotaline treatment had no effect on release rate, and 3.4. Release of ET peptides in coronary effluent and endothelium disruption reduced the production of big ET-1 interstitial fluid to about one half (Fig. 5A) . The resulting big ET-1 concentration (Fig. 5B ) was about ten-fold higher than the The effect of monocrotaline treatment on the release of corresponding concentration of mature ET-1 (Fig. 3B ). ET-1 in coronary effluent and the effect of endothelium disruption are shown in Fig. 3A . Both in control and 3.5. ET-1 and big ET-1 levels in myocardial hypertrophic hearts, release of ET-1 was stable and similar homogenate over 2 h, and disruption of endothelium reduced it to |30% in both cases. Accordingly, the respective ET-1
The levels of ET-1 and big ET-1 in ventricles are concentrations in coronary effluent were similar (Fig. 3B) . depicted in Fig. 6 . Monocrotaline treatment had no in- mortem. The surviving animals appeared quite normal and were sacrificed at 10 weeks. These animals developed no peritoneal or pleural effusions and had similar lung 3.6. ANP weights as controls, but showed marked right-ventricular hypertrophy. These features, together with the markedly The effect of monocrotaline treatment on the release of increased levels of ANP in plasma and coronary effluent ANP in coronary effluent is depicted in Fig. 7 . In the (Figs. 2 and 7 ) probably indicate that these animals were treatment group, ANP release was increased |5-fold, and in a state of compensated heart failure [26] . Upon perfudisruption of endothelium had no effect (n59; p,0.05).
sion in vitro, baseline LVDevP and coronary function were levels of both peptides were increased about two-fold in treated animals. Therefore, the present data do not support indistinguishable between control hearts and hearts from a role for myocardial ET-1 in the development of righttreated animals. ventricular hypertrophy in rats approaching adulthood. Release of peptides was measured in the coronary Rather, they point to a possible role for circulating ET-1 effluent and interstitial transudate, and rates of release were because plasma levels of both peptides were higher in converted to the respective concentrations in both fluids animals with myocardial hypertrophy. A possible increase (Figs. 3-5 ). As in several previous studies from our in ET-1 and big ET-1 in the hypertrophic right heart could laboratory using this experimental setup, we have found a have been missed by sampling coronary effluent at the considerably higher rate of release of endothelins to the coronary sinus which contains effluent from the right and luminal than to the abluminal side, but because of the the left heart. However, this is unlikely as evident from much lower transudate flow rate (#1%) than effluent flow measurements of big ET-1 and ET-1 in right-ventricular rate, the resulting concentrations were reversed, i.e. about tissue which showed a reduced, rather than increased, 5-fold higher in the transudate than the coronary effluent.
content of peptides per unit wet weight compared to Therefore, cardiac luminal release of endothelins may have controls. The latter finding is likely explained by the contributed to the levels of ET-1 and big ET-1 measured in ''dilution'' of big ET-1 and ET-1 in hypertrophic ventricuplasma (Fig. 2) . lar tissue and indirectly also supports the conclusion that The present data clearly indicate no change in ET-1 and the production of both peptides was not increased in right big ET-1 release in hearts of animals injected with ventricles as a result of right-heart haemodynamic overmonocrotaline compared to controls, whereas plasma load. Hence, the additional ET-1 and its precursor found in vestigations. The expression of ET receptor mRNA was B perceptibly increased in ventricles of monocrotaline-treated rats compared to controls (Fig. 2 in [35] ) and reduced in pulmonary arteries following ET converting enzyme inhibition [36] . After disruption of the coronary endothelium, release of both ET peptides was greatly reduced, indicating that the major portion of cardiac ET-1 and big ET-1 was derived from coronary endothelial cells. We have previously shown that the procedure used for disrupting the vascular endothelium leads to total abolishment of endothelium-dependent relaxation [22] . The origin of the small remaining release of ET-1 into the coronary circulation was not ascertained; however, previous studies have shown that myocytes generate the peptide in culture [37] , and following ischemia, in vivo [38] . The reasons for the reduction of left-ventricular pressure development after collagenase inotropic effect in isolated heart preparations [8] .
absence of endothelium. Results are means6SEM, n59 hearts in each Although the isolated perfused rat heart is capable of case.
producing angiotensin II in the presence of renin [39] or renin and angiotensinogen [40], we found no angiotensin II the plasma of hypertrophic rats (Fig. 2) is unlikely to be of in coronary effluents or interstitial transudate in the hearts cardiac origin.
of rats subjected to vehicle or monocrotaline treatment. The present results extend previous observations using Similarly, van Gilst et al. found no angiotensin II in the ET receptor antagonists. Thus, the progression of carcoronary effluent of untreated hearts [41] . In a previous diopulmonary alterations following monocrotaline treatstudy using a model of left-ventricular hypertrophy due to ment was attenuated, albeit not reversed, by the selective aortic insufficiency, left-ventricular angiotensin II was also ET -receptor blockers BQ-123 [27] , CI-1020 (previously, unchanged, but specific angiotensin AT receptor blockade A 1 PD 156707) [28] , LU 135252 [29] or FR139317 [30] . with losartan antagonized the hypertrophic response and Similarly, monocrotaline-injected rats gavaged once daily the rise in left-ventricular ET-1 [42] . These latter data as with bosentan, a mixed ET / ET receptor antagonist, well as the data reported in this paper suggest that it is A B showed blunted pulmonary hypertension, less pulmonary blood-borne rather than local angiotensin II that interacts vascular thickening, and reduced right-ventricular hyperwith the local ET system to produce the hypertrophic trophy [31] . Measurements of ET-1 mRNA levels in response. Studies using AT and ET receptor blockers are 1 various tissues following exposure to monocrotaline indinecessary to further probe the role of the interaction cated two-to three-fold increased expression in ventricles between the angiotensin and ET systems for the developand kidney [27, 32] , pulmonary vessels [33] and lung [34] , ment of hypertrophy in the monocrotaline model. although in the latter organ reduced levels of peptide and Endothelin is a potent secretagogue for ANP in cultured mRNA for ET-1 were also observed [27] . These data, rat atrial myocytes and isolated hearts [43, 44] , and the together with the consistent finding of increased plasma concentration of ANP in plasma has been found to be levels in monocrotaline-treated rats and the similar rates of increased in patients [45] and in rats with heart failure ET-1 and big ET-1 release in control and treated animals [20, 26] . In agreement with the latter animal studies, we reported here, suggest that the right-ventricular hyperfound two-fold higher plasma ANP levels in monotrophic response in rats with pulmonary hypertension crotaline-treated rats (Fig. 2) , all of which showed signs of results from an endocrine action of circulating rather than right-heart hypertrophy but had no pleural or peritoneal cardiac-derived ET-1. The fact that the level of ET-1 was effusions that would be indicative of heart failure. The not increased in right-ventricular hypertrophic tissue (Fig. cardiac tissue levels of ANP in hypertrophic or failing 6) does not contradict this view, because increased in vivo hearts, measured in extracts of homogenized tissues, have plasma levels of endothelins (Fig. 2) , likely reflecting been controversial. In renal hypertensive rats, Matsubara et enhanced synthesis outside the heart, would not translate al. showed a two-fold increase in the level of ANP in into a measurably higher concentration in total heart hypertrophied right ventricle, a seven-fold increase in homogenate.
extracts of hypertrophied left ventricles, and a considerable The role of ET receptor subtypes in mediating the decrease in left and right atria [46] , whereas in carhypertrophic response has been the subject of few indiomyopathic hamsters, Franch et al. found a reduced level
